Reddit Posts
Bullish News for Psychadelic Stocks? "FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs..."
Special Situations for Thursday: $DSS, $ATAI, $MIGI, $BIOL
Special Situations for Thursday: $DSS, $ATAI, $MIGI, $BIOL
Atai stock rises amid restructuring with ~30% job cuts (NASDAQ:ATAI)
Mexican Senator To File Psychedelics Legalization Bill, With U.S. Congressman Backing International Reform Push
What's your opinion on ATAI and other psychedelic medicine companies?
Unlock The Mind - Solving America's Mental Health Crisis with $ATAI (Atai Life Sciences). Full DD on the Psychedelic sector potential. 🍄
Unlock The Mind - Solving America's Mental Health Crisis with $ATAI (Atai Life Sciences) Full DD on the Psychedelic sector potential. 🍄 DD
A Look at "R-Ketamine" Drug Development Ahead of $ATAI's PCN-101 Phase 2a December 2022 Data Readout (Psychedelic Stock)
ATAI Life Sciences what do you guys think?
What is your opinion on small cap biotech stocks like TSHA and ATAI?
ATAI, A Company with a lot of potential for short term and long-term gains.
What’s your favorite Magic Mushroom Penny Stock? A few I’ve been looking into are FTRP, SEEL, CYBN, CMPS, GHRS, ATAI, MNMD.
Cathie Wood makes her first investment in Psychedelics
$IGXT Due Diligence - Not your average biotech play. Dissolvable Oral films with medicine on them, faster onset, compliance, skip first pass digestion (similar to injections).
The Upcoming Psychedelic Sector Opportunity 🍄 (FDA Phase 2b data readout in November 2021)
The Upcoming Psychedelics Sector #ShroomBoom 🍄 (November 2021 FDA Phase 2b Catalyst)
$IGXT Up 43% in the last four trading sessions despite heavy short volume
Update On $IGXT since my last post, up about 41% since.
$IGXT Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease.
$IGXT; Pennystock that has turned the corner and gone from R&D to Manufacturing. Oral film Delivery system (Oral films that go directly to bloodstream, Skip first pass digestion). The market hasn't caught onto this company yet..
IntelGenx Receives U.S.$6 Million in Additional Loans from atai Life Sciences and Conditional Approval to Graduate to Toronto Stock Exchange!!!
$ATAI psychedelics getting ready to go apeshit.
IntelgenX officially launches Rizaport in spain!!
Mentions
Psychedelic therapeutic stocks, ATAI and CMPS also doing well past year after taking big dumps post IPO. Lots of trials in the works and potential for big boys to scoop them up.
DFTX is currently the most overbought stock in this industry. I'm much more bullish on ATAI personally
Psyence and ATAI both have ibogaine treatments in their pipeline.
ATAI. Best-in-class psychadelic biotech company.
I bailed on a lot of speculative stuff (aka stuff I heard about on Reddit) but am holding on to the ones I believe in. Biggest position is 8k shares of ATAI. Down $3k now, should have taken profits this fall when it was up $14k 🤦♂️🤦♂️. I learned a LOT about investing and trading this past year so it hasn’t been all bad. It’ll all come back, learning to be patient.
All this craziness makes me keep buying psychedelic stocks. The amount of PSTD, Anxiety and Depression is insane. Only the serious players though (because there is a lot of crap).... DFTX and ATAI for the win.
Oddly my psychedelic plays are doing good. DFTX and ATAI. All things considered.
Look into ATAI. Possibly my greatest find yet. Backed by a couple of powerful tech billionaires. It’s going to go nuclear.
Glad to see ATAI on there.
My view, there are two companies with more advanced pipeline. CMPS will likely be approved this year and ATAI is 2-3 years behind.
$ATAI NEWS Shares of drugmaker AtaiBeckley ATAI.O rise 1.29% to $3.94 premarket ** Co says its experimental depression drug BPL‑003 will enter late‑stage testing in Q2 2026 after positive FDA feedback ** Says BPL‑003 is aimed at treatment‑resistant depression, a severe form of the condition where common therapies do not work ** Adds nasal‑spray drug showed rapid, lasting benefit in mid‑stage study, with effects seen in two days and lasting up to eight weeks ** Two upcoming 12‑week trials, plus a year‑long extension, will test the drug against placebo - ATAI ** Co reaffirms cash runway into early 2029 and reports progress on anxiety drug EMP‑01 and depression drug VLS‑01 ** ATAI rose about three-fold in 2025
Is it finally time to dump ATAI for good? The PT of $14 followed immediately by the offering...
ATAI is gonna pop tomorrow
ATAI is supposed to pop off I heard
# ATAI. This news just came out: [https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-announces-successful-end-phase-2-meeting-bpl-003](https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-announces-successful-end-phase-2-meeting-bpl-003)
ATAI is getting ready to pop 🚀
>He also said they did see improvement in social anxiety, about on par with existing treatments Normally this would ruin chances of FDA approval. However, ATAI's focus is on *treatment-resistant* depression and anxiety. So as long as its psychedelic pipeline works (and traditional SSRIs don't), it meets the required use case - and investors sell-off was overblown. I exited ATAI in early October but will trim both SLS and ABOS profits to buy back in.
Wow wtf is happening with ATAI. This stock never stops fucking me.
ATAI news this morning https://www.stocktitan.net/news/ATAI/atai-beckley-announces-positive-topline-results-from-an-exploratory-oluglj2ehb8t.html
ATAI will moon today, encouraging result of EMP-01
ATAI just got a new CFO
ABOS and ATAI. They're giving me good vibes
Or $ATAI if you're worried about FOMOing into $CMPS. I'm about 80-20 $ATAI $CMPS. $CMPS will likely be first to market but $ATAI short acting psychedelics to compete with Spravato ketamine is where the money's at.
Why would you describe yourself as a depressed person? Are you still depressed? I would suggest looking into this therapy as a therapeutic option as ketamine is short lived but data showed good long term data for CYBIN. They also combine this drug with integrated psychotherapy so the affects do not wear off compared to Ketamine. You are in luck, $DFTI also got BRT designation and will have phase 3 trial out and they are using LSD!!!!!! analogues. $ATAI is doing trials on MDD and GAD with DMT analogue. They also received breakthrough designation and is up 300-400% in past 2-3 years.
Forget everything check out ATAI and HELP, both biotech. CYBIN can explode to 5- 10 times in 12 months while ATAI can explode 5-10 in 2-3 years. ATAI already up by 4-5 times in last 1-2 years. These drugs can literally change their field and possibly the world as we know it. Check them out
“ATAI’s closed at 3.80 Breaking though that at open $3.80 with volume, That’s our ticket to continuation, back toward those six-month highs around $6.75. Below? Back to $3.50 chop. Buying need to buy more tmrw 🚀
Might be a good quarter for ATAI.
ATAIBeckley is interesting, but honestly the real story is just catalysts. These psychedelic names move like crazy around Phase 2 readouts, protocol updates, FDA meetings, etc. If you’re watching $ATAI, I’d focus less on the “close to the admin” stuff and more on what’s actually coming up on the clinical timeline. I’ve been using tickr-bio as a biotech event tracker to keep those dates straight instead of digging through 10 PDFs.
Bought my BBAI, SMCI, ATAI and PLTR flash sale yesterday. Let’s go
MSFT, GOOG and then my mushy favorites CMPS, ATAI, DFTX
ATAI jumping, TELO is next
I think ATAI is about to come back up too.
My point is, if you’re down, you’re down. If you had $100 and now it’s $50, you have $50. $50 + hope x regret = $50. You can tie up your money and leave it where it is, inactive and without actionable catalysts in the near term or you can move it into an instrument with near term catalysts. If ATAI kicks you can always reinvest. If I were long term with conviction on ATAI, and it dipped, I’d buy more, but I’m short term, and tomorrow is always fresh without any mistakes in it.
But what if a loser today has potential to be a winner down the road? Case in point: I’m down $3500 with ATAI Beckley but believe in the company’s mission and potential. And there are real catalysts this year that could move the needle substantially. Does it serve me best to cut my losses or hold in hopes that these catalyst turn my losses into gains?
Research the M&A that happened in the last year, you’ll see real money is flowing back and the valuations are rising. To name a few tickers I personally mentioned here this year: OBIO (at 2.40), ATAI (at 2.05), CMPS (~3), MRVI (2.20), all had even higher highs. The only one of those I’m still holding is OBIO, but the stock I’m really high and long on is DRTS
ATAI. Up 216% yoy, and drugs haven't even hit the market yet. Rescheduling of marijuana likely to help too
Been a while since I researched, but if memory serves CYBN was one of the leaders in FDA trials of LSD for PTSD treatment. I believe they were also pursuing treatment of LSD and other psychedelics for depression. Specifically, people with depression that SSRI's did nothing for. Another company to look into is ATAI. Backed by Peter Thiel. Their model was 1) inorganic growth by acquiring a lot of other psychedelic businesses and 2) pursuing a patent on synthetic psilocybin molecule. Peter Thiel gave a talk a couple years ago at Davos about psychedelics. Right now there's a lot of pie in the sky with psychedelic stocks, but if these businesses can achieve what they're pursuing: gold mine.
ATAI. Up 221% yoy. Weed rescheduling and postitive drug trial results will boost again in 2026
ATAI (up 221% yoy). Weed rescheduling and drug trial progress will boost again
Me thinks ATAI and psych stocks are going to moon again in 2026 (up 195% ytd). Recent ganja rescheduling is another good sign
$CMPS, $ATAI, $CYBN - Psychedelic medicine is the mental health breakthrough the world needs.
97% of my portfolio is VOO but 3% are my fun individual stocks and I will continue to buy psychedelic industry stocks. MNMD, ATAI, CMPS etc
Patented synthetic psilocybin polymorph (unique crystalline structure) going through FDA clinical trials. It's currently in the second Phase 3 trial, the final stage before potential approval. On top of that you have bipartisan support in Congress, RFK Jr publicly advocating for it, and the head of the FDA himself has said we need to be looking into these compounds. Lastly, FIVE of these compounds now have Breakthrough Therapy designation which further accelerated approval and massively raises approval chances. Psychedelic Drugs with FDA Breakthrough Therapy Designation 1. CYB003 (Deuterated Psilocybin analog) - $CYBN (soon to be $HELP) A novel psilocybin-derived compound developed by Cybin for major depressive disorder (MDD). Received Breakthrough Therapy designation from the FDA. Designed to have a faster onset and shorter duration than classic psilocybin. Currently in advanced clinical trials (Phase 3) for MDD. � Wikipedia +1 2. MM120 (LSD-based compound) - $MMED A specially formulated LSD-derived drug being developed by MindMed for generalized anxiety disorder (GAD). Granted Breakthrough Therapy status based on promising clinical data. � Forbes 3. Psilocybin (COMP360; various formulations) - $CMPS Psilocybin itself has received Breakthrough Therapy designations through specific company programs (e.g., COMPASS Pathways’ COMP360 for treatment-resistant depression and Usona Institute’s psilocybin program for major depressive disorder). These designations date back to earlier in the decade and continue to support ongoing Phase 3 research. � Grass Roots NLP +1 4. 5-MeO-DMT (BPL-003) - $ATAI A novel intranasal formulation of 5-MeO-DMT developed by Atai Life Sciences and Beckley Psytech has recently been reported to receive FDA Breakthrough Therapy designation for treatment-resistant depression. This reflects growing interest in rapid-acting psychedelic treatments beyond psilocybin and LSD. �
Psychedelic medicine should have a massive year, especially if Compass' lead candidate gets FDA approval. $CMPS $ATAI $HELP
All I'm seeing is I should have been smart and loaded up on ATAI on the dip.
$ATAI and $CYBN for short acting clinical psychedelics
Looking for feedback on the following if anyone cares to share their insight. much appreciated AREC QBTS ATAI
EU markets are open.. is everybody sleeping op ATAI? [https://finance.yahoo.com/news/h-c-wainwright-maintains-buy-133916105.html](https://finance.yahoo.com/news/h-c-wainwright-maintains-buy-133916105.html)
Buying back into ATAI over 6 was a fuckin horrible idea.
Yes, with ATAI and MNMD recently. Jumped into those way too early, and was down at least 70% at some points, but walked away with a 25% ROI after a few years.
Parts of it. My IMNM was up. ATAI continues to fall.
ATAI - 60% LYFT - 8% CorMedix - 47% AMAZON - 15% Any feedback?
Throw some on 2027 ATAI calls. Was planning to do the same, and seems like good time to with it being down last few days. Good luck
Anyone know what is happening with ATAI?
ATAI ..thiel is heavily invested , rfk hates ssris ….NIH gave them a multi year grant …so many catalysts
ATAI. Psychedelic medicine is gaining steam and this is the best of the breed. Fast acting, safe and effective therapies are going to go mainstream in the next 5-10 years. Big pharma has only begun to catch on (see J&J's Spravato blockbuster ketamine therapy). Love them or hate them, the current administration is fast-tracking this stuff. Philosophically a very anti-AI investment, but that only boosts my conviction.
gotta yank my $$$ (except ATAI) out to do a house payment. see you guys in 6 months when I can "save" again.
You kidding me?! $MNMD and $ATAI...
I recommend ATAI a few times last week. Up 17% today (plus 6% more after market). You’re welcome.
Whoever downvoted me earlier when I said buy ATAI after they got FDA approved DMT, I hope the wheels on your car fall off
ATAI saved me from POET loss
PCSA PRSO ADAP DVLT CAN ATAI .. all have had some green during these blood bath days. Means ppl have some conviction despite fear
DMT got FDA approval, buy up some ATAI if you’ve met any deemster jesters 🔥
The AH movement on $ATAI is more insane than my EX GF LOLZ
Hell yea, ATAI is below 5$ again!
I think of you every day when I check my investment account and see it up by another $25k. +$600k and counting between ATAI and CMPS
ATAI - Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside. Psychedelic treatments! UP over 15% today.
ATAI - Up about 10% today and continues to rise. PT at $12, staying long, bought in at 3.08.
ATAI is saving my portfolio today
BPL-003 has a similar structure and effects as psilocybin and was granted a breakthrough therapy designation (BTD) back in 10/2018. There's a strong possibility that ATAI gets the BTD for BPL-003. BTD's are most likely to occur after completion of phase 2, and ATAI's BPL-003 ended in July 2025. According to corporate updates from ATAI Life Sciences, the company planned to hold an End-of-Phase 2 (EOP2) meeting with the FDA to discuss the BPL-003 program in the third quarter of 2025. As of early October 2025, no official outcome from this meeting has been announced publicly. Key context on the meeting: * **Purpose:** The meeting was to discuss the path forward for Phase 3 trials for BPL-003, a therapy for treatment-resistant depression (TRD). * **Timing:** The meeting was scheduled for the second half of 2025, after atai and Beckley Psytech announced positive Phase 2a and 2b data for BPL-003. * **Potential outcome:** Analysts and investors have discussed the possibility that atai could receive Breakthrough Therapy Designation (BTD) during this time, which would expedite the development process.
This Reddit post is one of the most accurate and well-balanced warnings I’ve seen about small-cap pharma investing — and it aligns with my firsthand experience. That said, it’s also worth noting how fascinating this sector has been over the past six months. The **biotech indices have more than doubled the S&P 500’s last 6 months returns** and even outperformed tech ETFs at times — and the sector just had its **best week in years.** I'm tracking and benefiting from real momentum in areas like **gene therapy**, **RNA therapeutics**, and even some **psychedelic-related neuroscience** plays. Plus many exciting one-product in-development companies are there to be found - if you know the business (few people do). A lot of companies that were absolutely crushed last year and very undervalued at the start of this year have been quietly recovering from the floor — some example names like *Ionis, Arrowhead, Nektar, ATAI, UniQure* have all had solid runs recently, some of course due to new Clinical Trial results (this is NOT a recommendation to buy in now given the price rises these saw - just examples) Of course, there are always the “one great drug” hopefuls and takeover dreams floating around — that’s part of the ecosystem. But what makes biotech so different from “normal” investing is just how unpredictable it is. Even when you know the science, the market reaction can appear irrational if you do not know the bigger picture/dynamics that will not obvious to most retail investors. For me, the safest (and most enjoyable) approach is a **portfolio mindset** — not betting too much on single miracles, but following themes, a bit like Big Pharma does with its pipelines. It’s risky, but fascinating — part science, part psychology. PS I'm ex-Pharma/Biotech and I invest entirely in Biotech - as it's the sector I know, even still - I keep most my initial biotech penny stocks to 1-2% of my portfollio
I keep dipping in and out of ATAI. It's alright, but there are better psilocybin plays out there.
No one talking about ATAI OR BCTX?
HOP on the ATAI train - Theil's next pump
Psychedelic Sector (Right Sector) - MNMD & ATAI (Right Stocks), Most all others wrong stocks in that sector.
ATAI all the way for me.Till deliberation day.
Sold some ATAI for EONR.
ATAI, CURA, PESO, PHIO. Original plays are still being called out. They're just drowning in noise.
IXHL goes down as the day's sole loss. DFLI, NUAI, PHGE, ATAI, and FEIM all performed admirably.
Sold Cap-XX (8% gain) to re-enter ATAI Life Sciences.